Chongkundang Bio Launches Next-Generation Botulinum Toxin 'Tyemvers'

Efficacy and Safety Demonstrated in Phase 3 Clinical Trial with Domestic Patients
Securing Competitiveness in Islamic Markets with the World's First Halal Certification

Chongkundang Bio announced on July 22 that it has launched the next-generation botulinum toxin preparation, 'Tyemvers' (TYEMVERS).

Botulinum toxin preparation 'Tyemvers'. Chongkundang Bio

Tyemvers is indicated for the treatment of moderate to severe glabellar lines and was developed based on a strain exclusively sourced from a European research institute. Notably, it uses a non-animal stabilizer instead of human serum albumin (HSA), fundamentally eliminating the risk of infection from blood-derived pathogens.

Chongkundang Bio explained that Tyemvers demonstrated both efficacy and safety in a Phase 3 clinical trial involving 300 domestic patients with moderate to severe glabellar lines. Through randomized, double-blind, active-controlled, and multicenter clinical trials, Tyemvers was proven to be non-inferior to Botox (onabotulinumtoxinA). There was no difference in the incidence of adverse reactions between the treatment groups, and no drug-related serious adverse events were observed. The results of this study were recently published in the SCIE-indexed international journal, Journal of Cosmetic Dermatology.

In particular, by thoroughly excluding animal-derived ingredients and adopting a non-animal (vegan) manufacturing process, Tyemvers became the world's first botulinum toxin preparation to receive halal certification from Indonesia's Halal Product Assurance Organizing Agency (BPJPH). The product was developed using a strain officially registered in GenBank, the genome information database of the U.S. National Center for Biotechnology Information (NCBI), thereby eliminating legal risks related to strain sourcing.

A Chongkundang Bio representative stated, "Tyemvers is a next-generation botulinum toxin preparation that has proven its safety and efficacy through systematic clinical trials based on a strain with transparent origins. Leveraging the world's first halal certification, we plan to expand into global markets, including Indonesia, the Middle East, Malaysia, and other Islamic countries."

This content was produced with the assistance of AI translation services.